Even though MSNs can usually be recognized as secure products, their use during therapy may cause side impacts in the body [ 1, 2, 29 ]. Due to their small size and large surface area, they may tend to accumulate in the body, or certain organs (liver, spleen, kidney, lung) and may even be toxic in higher concentrations, which is a clear disadvantage [ 1, 4, 27 ]. The silanol groups (Si-OH) on their surface can interact with the phospholipid layer of the cell membrane, thereby causing cell lysis or, in extreme cases, hemolysis [ 4, 8 ]. In severe cases, the lack of hemocompatibility can also cause issues [ 2 ]. Overall, indications of cytotoxicity, haemotoxicity, and genotoxicity were also found [ 4, 8 ]. That is why the biocompatibility of all comparable preparations must be strictly controlled [ 2, 4, 27 ]. The physicochemical features (particle size, particle morphology, surface chemistry, pore structure, etc.) of nanocarriers also have a major impact on toxicity [ 2, 4, 8, 30 ]. Additionally, further attention must be paid to the biological influences of their decomposition products, because they may also cause unwanted side influences [ 1 ]. The breakdown of silica nanoparticles in the body can take up to a few days. The opening hydration is followed by hydrolysis, and, in the end, they are excreted in the urine in the form of silicic acid [ 1 ]. Nevertheless, the literature is contradictory in this regard [ 31 ]. Some experiments show no considerable cytotoxic effect [ 18, 31 ], while other experiments say otherwise [ 23, 32 ]. For example, an in vitro study was performed with multiple concentrations, surfaces, and particle sizes (60 nm, 100 nm, 300 nm) of MSNs, with an exposure time of 72 h [ 18 ]. This study shown no significant cytotoxic influence in any of the cell lines tested (human cervical (HeLA), epithelial lung (A549), and glioblastoma (U251)) [ 18 ]. Ismail et al. investigated the cytotoxic effect of silica nanoparticles in vivo in mouse models [ 33 ]. Amorphous silica nanoparticles were administered to the animals orally, at a dose of 150 mg/kg/day, for 3 months. Based on these mouse models, no toxic effects were detected under sub-chronic treatment of the nanoparticles [ 31 ]. In another study, particle size (15 nm, 60 nm, 200 nm) dependent impact was observed on cellular viability in all four cell lines tested (THP-1 derived macrophages, A549 epithelial cells, HaCaT keratinocytes, and NRK-52E kidney cells) [ 23 ]. Smaller particles caused notable toxicity on each cell line, after the exposure time of 24 h, in contrast to the larger particles, which demonstrated no cytotoxic impact [ 23 ]. A comparable outcome has been published to verify the toxic characteristic of mesoporous silica. In this in vitro study, the researchers investigated the effect of MSNs with an average size of 7 nm on cell viability at three different concentrations. After 72 h of exposure, only the highest concentration (62.5 µg/mL) caused a substantial decrease in cell viability of human lung fibroblast cells. This toxicity occurred in a time- and dose-dependent manner [ 32 ]. In an in vivo mouse model, MacCuaig et al. presented coating-dependent impacts after repeated intravenous administration of MSNs. Chitosan-coated MSNs induced minor organ changes and were the most biocompatible. Uncoated and especially PEG-coated MSNs (especially 2K PEG) moderately augmented pre-existing vascular or organ lesions, implying that PEGylation has the potential to augment chronic risks, while chitosan enables safer long-term use [ 34 ]. An in vitro study of Barguilla et al. exposed epithelial lung cells to bare, PEG-functionalized, or galacto-oligosaccharide-functionalized MSNs for eight weeks. There was no reported long-term DNA damage, but malignant-like alterations like anchorage-independent growth, boosted migration/invasion, and secretome-facilitated tumor promotion were triggered by PEG- and GAL-functionalized MSNs. Naked MSNs did not cause such alterations and were determined to be safer [ 35 ]. Coating, on the whole, exerts a significant impact on the safety of MSNs. Uncoated MSNs are relatively innocuous; the most biocompatible coatings were achieved with chitosan, but PEG and carbohydrate functionalization can be dangerous in the long run, from vascular toxicity in vivo to tumor-promoting activity in vitro [ 34, 35 ].
Fumed Silica Manufacturer: Production Process, Key Grades and How to Choose
High Purity Quartz Market 2026: Supply, Demand and Price Outlook
7.1.1. Low-Dose Tablets
Silica as a Rheology Modifier: How It Controls Viscosity and Flow
Got 2025 Aug 17; Revised 2025 Sep 15; Accepted 2025 Sep 15; Collection date 2025 Sep.
Tosoh Silica: Product Range, Applications and Key Grades
Funding Statement
Matting Agent for Coatings: Types, Selection Guide and Performance Comparison
Acidic Silica Sol: Properties, Stability and Applications
What is silica (SiO₂)?
microsilica for cement
Things to Be Aware of
What is the difference between fumed silica and precipitated silica?
custom silica
What drives silica raw material prices?
silica quote
The immune activation through functional nanocarriers is realized by interactions with innate immune cells such as macrophages, neutrophils, and complement proteins. Immune recognition triggers inflammation, immune responses, or even swift clearance, thus presumably constraining therapeutic effects. Surface properties, such as chemical composition, topography, and charge, may influence the immune cell activation and binding specificity. The possible immune interactions need to be well characterized for the development of stealth and immunocompatible nanoparticles [ 82 ]. Immune-derived side influences, such as cytokine release and complement activation, potentially corrupt the safety and the effectiveness of drug delivery [ 80 ]. Other problems that may affect nanoparticle penetration and the effectiveness of targeting are the heterogeneity of the target tissue and tumor microenvironment. Problems of stability, biodegradation rates, and nanoparticle agglomeration may also affect the effectiveness of action [ 80 ].
Cite this article: Silica Raw Materials News. "Silicon Carbide vs Silica: Differences in Hardness, Structure and Uses
." Published 2026-11-20 12:41:09. /news/article.html Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.